Psychiatric Services · 2016 · 46 citations · 4 references
PharmacyPharmaceutical PolicyPharmacotherapyDrug Approval ProcessesEvidence-based PracticePsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyClinical TrialsSchizophrenia PharmacotherapyTreatment-resistant Psychiatric DisordersAntipsychotic EfficacyAntipsychotic Medication ManagementAntipsychotic Medication UseClozapine PharmacologyMarketing Campaign TargetingMental Health EvidencePharmaceutical Marketing RegulationPsychotropic Medication Prescribing
Clozapine remains the only medication approved for treatment-resistant schizophrenia. But underuse is the norm. In 2010, the New York State Office of Mental Health began a multifaceted initiative to promote the evidence-based use of clozapine. From 2009 to 2013, in the absence of a well-funded pharmaceutical marketing campaign, the proportion of new clozapine trials among all new outpatient antipsychotic trials increased 40% among adult New York Medicaid recipients with a diagnosis of schizophrenia. The largest gains occurred in state-operated clinics. New York's experience demonstrates the feasibility of making clozapine more accessible to patients who stand to benefit most.
4
Psychiatrists’ attitude towards and knowledge of clozapine treatment
Jimmi Nielsen, M. Dahm, Henrik Lublin et al. · Journal of Psychopharmacology · 2009 · 213 citations
Geographic and Clinical Variation in Clozapine Use in the United States
T. Scott Stroup, Tobias Gerhard, Stephen Crystal et al. · Psychiatric Services · 2013 · 128 citations